Galecto Inc (GLTO) USD0.00001
Sell:$3.97Buy:$4.25
$0.08
(2.02%)
- This stock can be held in a
Stocks and Shares ISA$0.08
(2.02%)$0.08
(2.02%)Company Information
About this company
Galecto, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel treatments for cancer and liver diseases. The Company’s pipeline consists small molecule drug candidates that target cancer and fibrosis signaling pathways, including an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of acute myeloid leukemia (AML). The GB1211, is also being developed for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
Key people
Key facts
- EPICGLTO
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS36322Q2066
- Market cap$5.23m
- Employees13
- Shares in issue1.32m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.